Patent · US Active

Compositions and methods for the treatment of cancer using a CD8 engineered T cell therapy

US11304978B2 · kind B2 · utility

0Cited by
4References
24Claims
0Family size

Assignee

Inventors

Key dates

Filing dateNov 20, 2020
Grant dateApr 19, 2022
Priority date—
Expiry dateJan 30, 2041

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2310/20
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Compositions comprising and methods for the treatment of cancer using a neoTCR based cell therapy with a CD8 expression construct.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.